Uribel Tabs Label Centers on Symptom Relief in Irritative Voiding
The DailyMed label for Uribel Tabs positions the combination as a symptom-directed product for irritative voiding, with use aimed at local inflammation, hypermotility, and pain accompanying lower urinary tract infections as well as urinary tract symptoms caused by diagnostic procedures. The formulation combines methenamine, benzoic acid, phenyl salicylate, methylene blue, and hyoscyamine sulfate in a coated oral tablet. Each component contributes a distinct pharmacologic role, and the label makes clear that the product is built around relief of urinary discomfort rather than broad antimicrobial substitution.
The label identifies the product as a human prescription drug label with no DEA schedule. It also states that the product is an unapproved drug other, and the FDA disclaimer notes that it has not been found safe and effective and that the labeling has not been approved by FDA. In practical terms, the medication’s use sits squarely inside a legacy combination-drug framework in which urinary symptoms are managed through multiple overlapping mechanisms.
A Five-Component Formulation Built for Urinary Acidity, Spasm Control, and Analgesia
The tablet contains methenamine 81.6 mg, benzoic acid 9.0 mg, phenyl salicylate 36.2 mg, methylene blue 10.8 mg, and hyoscyamine sulfate 0.12 mg. Those ingredients are not interchangeable. They are arranged to change the urinary environment, reduce spasm, blunt pain, and provide weak antiseptic activity through distinct biochemical pathways.
Hyoscyamine sulfate is described as a parasympatholytic that relaxes smooth muscle and produces an antispasmodic effect. It is well absorbed from the gastrointestinal tract, rapidly distributed through body tissues, and mostly excreted in urine within 12 hours, with 13% to 50% unchanged. Hepatic biotransformation and moderate protein binding complete its profile. In a patient with painful urinary urgency or bladder spasm, antimuscarinic relaxation is the component most likely to ease the sensation of involuntary contraction.
Methenamine provides the label’s most pharmacologically conditional effect. It degrades in an acidic urine environment, releasing formaldehyde that provides bactericidal or bacteriostatic action. Seventy to 90% reaches the urine unchanged, and at pH 5 approximately 20% becomes formaldehyde. The label also makes the pH threshold clinically important: methenamine is not clinically significant at pH greater than 6.8 because it does not hydrolyze effectively there. The requirement for acidic urine explains why benzoic acid is included, since it helps maintain the acid pH needed for methenamine degradation.
Methylene blue possesses weak antiseptic properties. It is well absorbed from the gastrointestinal tract, rapidly reduced to leukomethylene blue, and 75% is excreted unchanged. Phenyl salicylate releases salicylate, supplying a mild analgesic effect for pain. The end result is a composite product aimed at symptom control through urine chemistry, antisepsis, and smooth muscle relaxation.
Safety Warnings Focus on Anticholinergic Burden and Urinary Retention
The contraindication section immediately draws attention to hypersensitivity to any ingredient. It also asks clinicians to weigh risk and benefit carefully in cardiac disease, especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis; gastrointestinal obstructive disease; glaucoma; myasthenia gravis; and obstructive uropathy such as bladder neck obstruction from prostatic hypertrophy.
One sentence in the warning section is especially direct: do not exceed the recommended dosage. If rapid pulse, dizziness, or blurring of vision occurs, discontinue use immediately. Those effects fit the expected antimuscarinic profile of hyoscyamine, and they are not minor inconveniences when the patient already has a vulnerable cardiovascular or genitourinary baseline.
The adverse reaction profile is consistent with that same pharmacology. Cardiovascular effects include rapid heartbeat and flushing. Central nervous system effects include blurred vision, dizziness, and drowsiness. Genitourinary effects include difficult micturition and acute urinary retention. Gastrointestinal effects include dry mouth, nausea, and vomiting. Respiratory symptoms can include shortness of breath or trouble breathing. Serious allergic reactions are described as rare.
A separate effect is easy to miss but clinically obvious once it appears: the medication can turn urine and sometimes stools blue to blue-green. The label states that this effect is harmless and will subside after medication is stopped.
Drug Interactions Track pH Shifts, Motility, and Enzyme Inhibition
The interaction section reflects the pharmacology of the combination. Because hyoscyamine slows gastrointestinal motility and delays gastric emptying, absorption of other oral medications may be decreased during concurrent use. Methylene blue inhibits multiple CYP isozymes in vitro, including 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4/5. The label notes that this may matter more with narrow therapeutic index drugs metabolized by these enzymes, including digoxin, warfarin, phenytoin, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus, although the clinical relevance of the in vitro interactions is unknown.
Urinary alkalizers and thiazide diuretics can make the urine alkaline and reduce methenamine effectiveness by inhibiting conversion to formaldehyde. Antimuscarinics may intensify hyoscyamine’s antimuscarinic effects. Antacids and antidiarrheals can reduce absorption of hyoscyamine and can also alkalinize urine, weakening methenamine’s activity. The label advises spacing these medications one hour apart from hyoscyamine.
Ketoconazole deserves separate attention because concurrent use with hyoscyamine may markedly reduce ketoconazole absorption; the label advises administering the combination at least 2 hours after ketoconazole. MAO inhibitors may intensify antimuscarinic side effects. Opioid analgesics may raise the risk of severe constipation. Sulfonamides may precipitate with formaldehyde in urine, increasing the danger of crystalluria.
Pregnancy, Lactation, Age, and Prolonged Use Require Caution
The precautions section is explicit about populations where caution is required. Hyoscyamine and methenamine cross the placenta. Animal and human studies concerning effects on pregnancy and reproduction have not been done, so fetal harm and reproductive effects are unknown. The label advises use in pregnancy only if clearly needed.
Breastfeeding guidance is similarly cautious. Problems in humans have not been documented, yet methenamine and traces of hyoscyamine are excreted in breast milk, so the drug should be given to a nursing mother with caution and only if clearly needed.
Infants and young children are especially susceptible to the toxic effects of belladonna alkaloids. Elderly patients may respond to usual doses of hyoscyamine with excitement, agitation, drowsiness, or confusion. The label also states that no studies have established the safety of prolonged use in humans, and no long-term animal studies have been performed to evaluate carcinogenic potential.
Dependence has not been reported, and abuse is not expected given the nature of the ingredients. The labeling closes on a familiar but important warning for combination urinary products: symptom relief does not erase the need to monitor for retention, anticholinergic toxicity, and interacting drugs that can change urinary pH or gastrointestinal absorption.